Pfizer’s experimental drug shows up to 12.3% weight loss in mid-stage trial – Reuters By Weight Loss Pfizer’s experimental drug shows up to 12.3% weight loss in mid-stage trial Reuters Pfizer’s stock fell after mixed response to weight-loss data for drug set to compete with Lilly’s Zepbound MarketWatch Pfizer’s $10B monthly GLP-1 bet generates competitive weight loss in phase 2b Fierce Biotech Brought to you by Google News. Read the rest of the article here Facebook Twitter Pinterest